FORM PTO 1449 (modified)	Atty. Docket No.	Serial No	
	X-16126		
INFORMATION DISCLOSURE CITATION	First Applicant		
IN AN APPLICATION	Jeffrey Alan DODGE		
	Application Date	Group Art Unit	
	US Nat'l Entry (if applicable)		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
	No 1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Pages or Relevant Figures Appear
	ΛΛ	US			
	AB	US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	No.1	Foreign Pitent Document Constry Code ² -Number ⁴ Kind Code ⁵ (Hinewa) MM-DD-YYYY		Name of Patentee or Applicant of Clied	Pages, Columns, Lines, Where	76
			Document	Relevant Passages or Relevant Fugures Appear		
	BA	EP 0 761 659	03-12-1997	Eli Lilly and Co.	Page 1, line 3 – line 7; examples 2, 5,6	
	BB	WO 95/10513	04-20-1995	Pfizer, Inc. et al.	Table 2, p. 76, 2 nd structural formula; p. 77, 2 nd structural abstract; example 19	
	BC	EP 0 729 951	09-04-1996	Eli Lilly and Co.	The whole document	
	BD	EP 0 731 100	09-11-1996	Eli Lilly and Co.	The whole document	
	BE	WO 03/053977	07-03-2003	Ortho-McNeil Pharmaceutical, Inc	Claim 1	
	BF	EP 0 791 591	08-27-1997	Eli Lilly and Company	Examples p. 5, line 52 – line 54; claim 1	
	BG	EP 0 761 669	03-12-1997	Eli Lilly and Company	Page 43; example 11b	

Extrainer

Signature

Delt: Considered

Delt: Co

to the text in contractions in approximate and in prices of the field Code of COSTO Met Doment of view implaine and MET 1981 to \$1 also COde of LOSTO Met Doment of view implaine and MET 1981 to \$1 also COde of LOSTO Met Doment of view implained and MET 1981 to \$1 also CODE and used for doment by the field of the lost of the impact analyses of the second school of the point doment. To find a find of the impact analyses of the impact

FORM PTO 1449 (modified)	Atty. Docket No.	Serial No	
	X-16126		
INFORMATION DISCLOSURE CITATION	First Applicant		
IN AN APPLICATION	Jeffrey Alan DODGE		
	Application Date	Group Art Unit	
	US Nat'l Entry (if applicable)		

		NON PATENT LITERATURE DOCUMENTS	
Examener Inmals*	No. 1	Include name of the sutbor (m CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, pound, serial, symposium, catalog, etc., data, page(s), volume-assue number(s) publisher, city and/or country where published.	Т6
	CA	Grese T. A., et al., "Synthesis and pharmacology of conformationally restricted raloxifiene analogues, highly potent selective estrogen receptor modulators", <i>Journal</i> of Organic Chemistry. Washington, USA, vol. 41, no. 8, pages 1272-1283, 1998.	
	СВ	Grese T. A., et al., "Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-Aryibenzothiophene core of raioxifene" Journal of Medicinal Chemistry, American Chemical Society, vol. 40, no. 2, pages 146-167, 1997.	
	CC		

Examin				Date Considered
Signatu				Annual Control of the
				Draw line through extation of and an conformance and not considered. Include copy of
this form	with n	est communication to applica	4	

to the task in interactions opposed. The Each Code of USFIO Point Decembed of view regulation as MRT 1964 to 18 and Code of USFIO Point Decembed of view regulation as MRT 1964 to 18 and Code of USFIO Point Decembed of view regulation as MRT 1964 to 18 and Code of USFIO Point Decembed of View regulation and the view of the regulation of the largest consistance of the point of construction of the view of the regulation of the largest consistance of the point of the regulation of the view of the regulation of the largest code of the largest code of the largest code of the largest code of the largest view of the regulation of the largest code of the largest view of the largest view